Medical/Pharmaceuticals
Pulsecare Medical Announces NMPA Approval of NxPFA™, the World's First Nanosecond PFA System, Ushering in the PFA 3.0 Era
SHENZHEN, China, Aug. 4, 2025 /PRNewswire/ -- Pulsecare Medical, a pioneer in cardiovascular intervention technologies, announced that its innovativeNxPFA™ nanosecond pulsed field ablation (ns-PFA) systemhas received marketing approval fromChina's National Medical Products Administration (NMPA). ...
2025-08-04 21:30
1780
Vatech Introduces 'Clever One' - A Game-Changing Dental Viewer Solution for the U.S. Market.
FDA-cleared AI dental platform integrates diagnostic support, treatment planning, and patient consultation into one seamless workflow TEANECK, N.J., Aug. 4, 2025 /PRNewswire/ -- Vatech, a global leader in dental imaging innovation, has officially launched 'Vatech® Clever One', its next-generatio...
2025-08-04 21:00
1751
Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth
MUNICH, Aug. 4, 2025 /PRNewswire/ -- Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany. The facility, located in Taufkirchen, strengthens Minaris...
2025-08-04 21:00
1923
Breaking Through Core CT Technology Barriers!
World-Class Innovations to Debut at 2025 Medtec in September SHANGHAI, Aug. 4, 2025 /PRNewswire/ -- A quiet revolution is underway in the field of high-end medical equipment, led byChina's growing innovation power. Core CT technologies, once dominated byinternational giants, are now being steadi...
2025-08-04 16:40
1503
NX Taiwan Awarded Healthy Workplace Certification by "Ministry of Health and Welfare"
- Received High Praise for Promoting Health Management and Contributing to Local Communities - TOKYO, Aug. 4, 2025 /PRNewswire/ -- Nippon Express (Taiwan) Co., Ltd. (hereinafter "NX Taiwan"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been accorded Healthy Workplace Certification by t...
2025-08-04 15:00
2089
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease
BEIJING, Aug. 3, 2025 /PRNewswire/ -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacr...
2025-08-04 14:29
1158
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease
BEIJING, Aug. 4, 2025 /PRNewswire/ -- Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canalic...
2025-08-04 14:05
1455
Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
HONG KONG, Aug. 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by bothChina's National Medical Products Administration (NMPA) and the ...
2025-08-04 13:56
1655
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE
SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially acce...
2025-08-04 09:28
2311
Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2
Clinical Trials and First-in-Human Studies
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025
/PRNewswire/ --Alveolus Bio
2025-08-04 08:00
2084
United Imaging Teases Multi-modality "Provider Success" Product Launches at AHRA 2025
The newly FDA-cleared uMR® Ultra and the uOmniscan™ are the first major announcements leading into the AHRA Annual Meeting inLas Vegas. HOUSTON, Aug. 3, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, will again be among the largest exhibitors at ...
2025-08-04 00:22
1674
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR
SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial inChina for its LY03021, which was filed throughChina's Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NE...
2025-08-03 18:23
2685
Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA
SHANGHAI, Aug. 1, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance fromChina's Na...
2025-08-01 22:00
3408
Everest Medicines Expands Strategic Investment in I-MAB
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall resp...
2025-08-01 21:02
3429
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIP...
2025-08-01 20:00
4828
Atombeat and BioDuro Announce Strategic Partnership to Launch an AI-Powered Platform for Accelerated Peptide Drug Discovery
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- On July 30, 2025, Atombeat Inc., a leading force in AI for drug discovery, andBioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO),announced a strategic collaboration to an AI powered platform for accelerated pe...
2025-08-01 18:08
2456
Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson's Disease
* The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects. * The results confirmed the favorable safety and tolerability profile of ...
2025-08-01 15:52
2106
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ -- On 31st July 2025, a unified consensus document for improving lung cancer care in theAsia-Pacific (APAC) region was officially launched inSingapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive ...
2025-08-01 15:02
2211
Herbalgy Trophy Wraps Up with a Thrilling 1-0 Victory Tottenham for Over Arsenal
Football Fever Grips Hong Kong as nearly 50,000 Fans Pack Kai Tak
Download high-resolution images: http://bit.ly/45dBPVk
2025-08-01 12:59
2725
Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for patients with high-risk neuroblastoma (HRNB)
This news is for Australian Media only * Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of eflornithine for post-maintenance treatment to prevent relapse in p...
2025-08-01 06:01
1965
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27